Paracetamol vs Panadol: Why Generic Medicines Work Just as Well

Quick answer: Branded medicines like Panadol and unbranded “generic” paracetamol contain the exact same active ingredient at the exact same strength. UK medicines law requires generic versions to be bio-equivalent to the branded original — meaning they deliver the same amount of active to the bloodstream, in the same way, at the same speed. Generics are typically much cheaper than the brand. The most common reasons people pay more for the brand are familiarity, packaging, and the formulation feel (some people genuinely prefer one tablet shape, coating, or excipient mix). Those are valid personal reasons — but they aren’t a clinical-effectiveness reason.

What “generic” actually means in UK medicine

When a pharmaceutical company develops a new medicine, they hold a patent on it for a fixed period (in the UK, typically 20 years from filing, though much of that is consumed by clinical trials and regulatory approval). During the patent period, only the originator can market that active ingredient under their brand name — the brand is the only legal route to the molecule.

When the patent expires, other manufacturers can apply to make the same active ingredient. To get a UK marketing authorisation as a “generic”, they have to show the MHRA that their version is bio-equivalent to the originator — that is, they have to demonstrate in head-to-head studies that the same dose of their tablet produces the same blood concentration of the active ingredient over the same time as the originator’s tablet does, within tightly defined statistical limits.

The MHRA only authorises a generic for sale in the UK once that bio-equivalence is demonstrated. The active ingredient is, by definition, identical to the branded product. The strength is identical. The route of administration is identical. The labelled indications are identical.

Paracetamol vs Panadol — the worked example

Panadol is a brand owned by Haleon (formerly part of GlaxoSmithKline). The active ingredient in Panadol Original tablets is paracetamol, 500 mg per tablet. Almost any UK supermarket or pharmacy will also stock its own-brand “paracetamol 500 mg” tablets — Boots-brand, Tesco-brand, Sainsbury’s-brand, the small white-and-pink generic packs, and so on.

All of those are paracetamol 500 mg per tablet. All have the same MHRA-authorised indications (mild to moderate pain, fever). All have the same maximum daily dose (eight 500 mg tablets in 24 hours for an adult, with at least four hours between doses). The price difference is often substantial — branded paracetamol can be five to ten times the price of the supermarket equivalent for the same number of tablets.

The same pattern is true across most over-the-counter medicines: ibuprofen vs Nurofen, loratadine vs Clarityn, cetirizine vs Piriteze, omeprazole vs Losec.

Why does the branded version cost more, then?

Three honest reasons account for most of the price gap:

1. Brand recognition and marketing. The branded company has spent decades and substantial budgets building consumer trust in the brand name. That cost is recovered through the price premium. People who know the brand often reach for it without comparing.
2. Packaging and presentation. Branded medicines often have more presentable boxes, blister packs that are easier to open, and clearer-printed patient information leaflets. The active ingredient is the same; the experience around it is different.
3. Excipient and formulation differences that some people genuinely notice. The active ingredient is identical in a generic and a branded tablet. The other ingredients (the binder, the coating, the colour, the flavouring of a chewable, the size and shape) may differ. A small number of people find one specific tablet easier to swallow, less bitter, or less irritating to the stomach than another. Those differences are real but usually small.

None of these are about the medicine working better. They are about the experience of taking the medicine and the cost of the brand-building work behind it.

When branded vs generic might genuinely matter

For a small number of medicines, the gap between bio-equivalent and indistinguishable is more meaningful. The MHRA flags this for clinicians and patients when it applies. Examples include:

• Some anti-epileptic medicines. The MHRA has classified anti-epileptic drugs into three categories that guide whether prescribers should switch between branded and generic versions. For Category 1 (carbamazepine, phenobarbital, phenytoin, primidone), the recommendation is to stick to the same branded or generic product to avoid even small fluctuations in blood levels that could affect seizure control.
• Modified-release versions of certain drugs. Different manufacturers use different release-control technologies — bio-equivalent in average terms, but with subtle differences that can matter clinically.
• Levothyroxine and a few other narrow-therapeutic-index medicines, where small dose variations have a measurable clinical effect.

For these specific medicines, your prescriber will usually specify a particular brand or version on the prescription. The pharmacist will dispense exactly that product. This is the exception, not the rule.

For everyday over-the-counter medicines like paracetamol, ibuprofen, loratadine, and most antacids, generic versions perform identically to the branded original.

Does the same logic apply to vitamins and supplements?

Partly. Vitamins and supplements are food, not medicine — so the regulatory framework is different. There is no MHRA bio-equivalence test for a vitamin C tablet from one manufacturer versus another.

What matters with supplements is:

• The form of the active ingredient. “Magnesium” on a label can mean magnesium oxide (poorly absorbed), magnesium citrate (well absorbed), or magnesium bisglycinate (well absorbed and gentle on the bowel). The form genuinely changes how much you absorb.
• The labelled dose. “1,000 mg of magnesium” can deliver very different amounts of elemental magnesium depending on the compound used. The elemental amount is what counts.
• GMP-certified manufacture. The manufacturer should be Good Manufacturing Practice certified, ideally with third-party testing for potency and contaminants.
• The brand’s transparency. A brand that publishes Certificates of Analysis, declares the country of origin, and answers your supplier-question emails is usually a better signal than a brand with vague marketing.

Camden Medicals’ position: paying more for the active ingredient form that absorbs better is usually justified. Paying more for a brand name without an active-ingredient or transparency justification is usually not.

How to compare confidently

1. Read the active ingredient name and strength on both products. They should be identical for generic substitution.
2. Check the patient information leaflet (PIL) — same active, same indications, same maximum dose.
3. Compare the price per tablet, not the pack price. A 32-tablet pack at £2 and a 16-tablet pack at £1 are the same value per tablet, even though the pack prices look different.
4. If you have a prescription or are buying for a child, an older relative, or anyone with a chronic condition, ask the pharmacist before switching brands — they will tell you the few cases where it matters.

The bottom line

For most over-the-counter medicines, the supermarket-brand or unbranded generic will work exactly as well as the heavily-marketed branded version. The active ingredient is the same. The MHRA has tested it. The savings can be real. For a small number of medicines (specific anti-epileptics, certain modified-release products, narrow-therapeutic-index drugs like levothyroxine), brand consistency does matter — and your prescriber or pharmacist will tell you when. For supplements, the question shifts from brand to form: what counts is which compound is in the tablet and how much elemental nutrient it delivers.

Related Camden Medicals reading

• Magnesium — why the form on the label matters →

• Vitamin D3 — D2 vs D3 and why the difference is small at typical doses →

• Vitamin B12 — methylcobalamin vs cyanocobalamin →

Sources and further reading

1. MHRA — Medicines and Healthcare products Regulatory Agency
2. MHRA Drug Safety Update — Anti-epileptic drugs: advice on switching between manufacturers
3. NHS — Medicines A to Z
4. British National Formulary (BNF)

Camden Medicals editorial. Information, not medical advice — talk to your pharmacist or GP about any medicine or supplement before switching, especially if you take prescribed medicines, are pregnant or breastfeeding, or have an existing condition. Suspected side effects can be reported to the MHRA via the Yellow Card scheme.